Every once in a while I check in to see what Northwest is up to. Recently there was a price spike but I didn't have time to look into it. It turns out there was nothing to justify it. Northwest Bio doesn't have the guts to issue an earnings PR, likely because they would have to admit they are making no clinical progress but continuing to feed cash from dilutive financings into Linda Powers' slush fund Cognate. They filed a 10Q as required but it contains nothing material regarding their progress or lack thereof in clinical trials. The one positive is that it does appear that the stock is in a death spiral with successive financings at lower and lower share price that are unable to keep up with the quarterly burn. The next 10Q should be interesting. Of course, given Northwest's history, there's no limit to the reverse splitting, nonsense PR spouting we might expect once Powers is backed into a corner.